Addison's Disease: Difference between revisions

No edit summary
No edit summary
Line 2: Line 2:
'''Original Editors '''-  [http://www.physio-pedia.com/index.php5?title=User:Elizabeth_Bohnert Elizabeth Bohnert] from [[Pathophysiology of Complex Patient Problems|Bellarmine University's Pathophysiology of Complex Patient Problems project.]]  
'''Original Editors '''-  [http://www.physio-pedia.com/index.php5?title=User:Elizabeth_Bohnert Elizabeth Bohnert] from [[Pathophysiology of Complex Patient Problems|Bellarmine University's Pathophysiology of Complex Patient Problems project.]]  


'''Lead Editors''' - Your name will be added here if you are a lead editor on this page.  [[Physiopedia:Editors|Read more.]]
'''Lead Editors''' - Your name will be added here if you are a lead editor on this page.  [[Physiopedia:Editors|Read more.]]  
</div>
</div>  
== [[Image:116268-050-1CDD8ABD.jpg|thumb|left]]Definition/Description  ==
== [[Image:116268-050-1CDD8ABD.jpg|thumb|left]]Definition/Description  ==


Addison’s disease is another name for primary chronic adrenal insufficiency. &nbsp;It is a condition where the adrenal cortex (the outer layer of the adrenal gland that produces mineralocorticoids, glucocorticoids, and androgens) is progressively destroyed, resulting in decreased secretions of the hormones.<ref name="Goodman, Fuller">Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. St. Louis: Elsevier; 2009.</ref><ref name="Kumar, Abbas">Kumar V, Abbas AK, Fausto N. Pathologic Basis of Disease. Philadelphia: Elsevier; 2005.</ref> &nbsp;Cortisol, a glucocorticoid, and aldosterone, a mineralcorticoid, are the primary hormones that are decreased with this disease, causing body wide metabolic disorders and fluid imbalances.<ref name="Goodman, Fuller" />  
Addison’s disease is another name for primary chronic adrenal insufficiency. &nbsp;It is a condition where the adrenal cortex (the outer layer of the adrenal gland that produces mineralocorticoids, glucocorticoids, and androgens) is progressively destroyed, resulting in decreased secretions of the hormones.<ref name="Goodman, Fuller">Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. St. Louis: Elsevier; 2009.</ref><ref name="Kumar, Abbas">Kumar V, Abbas AK, Fausto N. Pathologic Basis of Disease. Philadelphia: Elsevier; 2005.</ref> &nbsp;Cortisol, a glucocorticoid, and aldosterone, a mineralcorticoid, are the primary hormones that are decreased with this disease, causing body wide metabolic disorders and fluid imbalances.<ref name="Goodman, Fuller" />  


<br>
<br>  


[Image courtesy of Britannica.com. Available at http://www.britannica.com/EBchecked/topic/6405/adrenal-gland]  
[Image courtesy of Britannica.com. Available at http://www.britannica.com/EBchecked/topic/6405/adrenal-gland]  
Line 38: Line 38:
•<span style="white-space: pre" class="Apple-tab-span"> </span>Salt craving<br>  
•<span style="white-space: pre" class="Apple-tab-span"> </span>Salt craving<br>  


[Image courtesy of University of South Carolina School of Medicine. Available at http://pathmicro.med.sc.edu/ghaffar/tolerance2000.htm]
[Image courtesy of University of South Carolina School of Medicine. Available at http://pathmicro.med.sc.edu/ghaffar/tolerance2000.htm]  


== Associated Co-morbidities  ==
== Associated Co-morbidities  ==
Line 55: Line 55:
[[Osteoporosis|Osteoporosis]] is more common among people with Addison's disease compared to healthy individuals because of the medical management with long-term steroid replacement therapy. &nbsp;Steroids have several effects on bones including increasing osteoclastic activity, decreasing osteoblastic formation, and decreasing the absorption of calcium in the intestines.<ref name="Adachi">Adachi JD, Bensen WG, Cividino A. Corticosteroid-Induced Osteoporosis. JAMWA. 1998; 53: 1-7.</ref>  
[[Osteoporosis|Osteoporosis]] is more common among people with Addison's disease compared to healthy individuals because of the medical management with long-term steroid replacement therapy. &nbsp;Steroids have several effects on bones including increasing osteoclastic activity, decreasing osteoblastic formation, and decreasing the absorption of calcium in the intestines.<ref name="Adachi">Adachi JD, Bensen WG, Cividino A. Corticosteroid-Induced Osteoporosis. JAMWA. 1998; 53: 1-7.</ref>  


<br> '''Bone Mineral Density T-Scores<ref name="Goodman, Snyder" />'''''<span class="Apple-style-span" style="line-height: normal; -webkit-border-horizontal-spacing: 1px; -webkit-border-vertical-spacing: 1px;">
<br> '''Bone Mineral Density T-Scores<ref name="Goodman, Snyder" />'''''<span class="Apple-style-span" style="line-height: normal; -webkit-border-horizontal-spacing: 1px; -webkit-border-vertical-spacing: 1px;"></span>
</span>''


{| width="400" border="1" align="left" cellpadding="1" cellspacing="1"
{| width="400" border="1" align="left" cellpadding="1" cellspacing="1"
|-
|-
| ''Status''
| ''Status''  
| ''T-Scores''
| ''T-Scores''
|-
|-
| Normal
| Normal  
| -1.0 or above
| -1.0 or above
|-
|-
| Osteopenia
| Osteopenia  
| -1.0 to -2.5
| -1.0 to -2.5
|-
|-
| Osteoporosis
| Osteoporosis  
| -2.5 or less
| -2.5 or less
|-
|-
| Severe Osteoporosis
| Severe Osteoporosis  
| -2.5 or less with 1 or more fragility fractures
| -2.5 or less with 1 or more fragility fractures
|}
|}


== Medications<ref name="Winqvist">Winqvist O, Rorsman F, Kampe O. Autoimmune Adrenal Insufficiency: Recognition and Management. BioDrugs. 2000; 13(2): 107-114.</ref>  ==
== Medications<ref name="Winqvist">Winqvist O, Rorsman F, Kampe O. Autoimmune Adrenal Insufficiency: Recognition and Management. BioDrugs. 2000; 13(2): 107-114.</ref>  ==
Line 82: Line 93:
•<span style="white-space: pre" class="Apple-tab-span"> </span>Intravenously administered hydrocortisone (100 mg), repeated every 6 hours for the first 24 hours  
•<span style="white-space: pre" class="Apple-tab-span"> </span>Intravenously administered hydrocortisone (100 mg), repeated every 6 hours for the first 24 hours  


•<span style="white-space: pre" class="Apple-tab-span"> </span>Intravenously administered rapid infusion of saline (2-4L) during the first 12 hours<br>
•<span style="white-space: pre" class="Apple-tab-span"> </span>Intravenously administered rapid infusion of saline (2-4L) during the first 12 hours<br>  


'''Maintenance Therapy:'''  
'''Maintenance Therapy:'''  
Line 88: Line 99:
•<span style="white-space: pre" class="Apple-tab-span"> </span>Glucocorticoid Replacement: 15-20 mg of hydrocortisone daily, divided into 3 or 4 doses to simulate normal adrenal secretions  
•<span style="white-space: pre" class="Apple-tab-span"> </span>Glucocorticoid Replacement: 15-20 mg of hydrocortisone daily, divided into 3 or 4 doses to simulate normal adrenal secretions  


•<span style="white-space: pre" class="Apple-tab-span"> </span>Mineralocorticoid Replacement: 0.05-0.1 mg of fludrocortisones daily<br>
•<span style="white-space: pre" class="Apple-tab-span"> </span>Mineralocorticoid Replacement: 0.05-0.1 mg of fludrocortisones daily<br>  


== Diagnostic Tests/Lab Tests/Lab Values  ==
== Diagnostic Tests/Lab Tests/Lab Values  ==
Line 148: Line 159:
|}
|}


[Chart courtesy of Merck.com. &nbsp;Available at&nbsp;http://merck.com/mmpe/sec12/ch153/ch153b.html]
[Chart courtesy of Merck.com. &nbsp;Available at&nbsp;http://merck.com/mmpe/sec12/ch153/ch153b.html]  


== Causes  ==
== Causes  ==
Line 160: Line 171:
== Medical Management (current best evidence)  ==
== Medical Management (current best evidence)  ==


Refer to [[#Medications|Medications]]
Refer to [[#Medications|Medications]]  


== Physical Therapy Management (current best evidence)  ==
== Physical Therapy Management (current best evidence)  ==


Unfortunately, there is very little information and research pertaining to the physical therapy management of patients with Addison's disease. &nbsp;The APTA's [http://www.hookedonevidence.org/index.cfm?CFID=40485899&CFTOKEN=77016608 Hooked on Evidence]&nbsp;yielded not a single article with the term "Addison's disease." Then&nbsp;[http://search.ebscohost.com/ EBSCOhost], [http://scholar.google.com/ GoogleScholar], and [http://www.proquest.com/en-US/ ProQuest] were all used with the search terms "Addison's disease" and "physical therapy" or "exercise" and there was only one pertinent journal article. &nbsp;Jakobi et al<ref name="Jakobi">Jakobi J, Killinger D, Wolfe B, Mahon J, Rice C. Quadriceps muscle function and fatigue in women with Addison's disease. Muscle &amp;amp;amp;amp;amp;amp; Nerve. August 2001;24(8):1040-1049.</ref> found that women with Addison's disease had similar maximum voluntary force of the quadriceps muscle compared to the control group of health individuals, however they had "altered contractile properties and decreased endurance compared with controls." Obviously, more research needs to be performed to determine the proper interventions that physical therapists should utilize to treat patient's with Addison's disease and also determine any limitations to treating these patients.  
Unfortunately, there is very little information and research pertaining to the physical therapy management of patients with Addison's disease. &nbsp;The APTA's [http://www.hookedonevidence.org/index.cfm?CFID=40485899&CFTOKEN=77016608 Hooked on Evidence]&nbsp;yielded not a single article with the term "Addison's disease." Then&nbsp;[http://search.ebscohost.com/ EBSCOhost], [http://scholar.google.com/ GoogleScholar], and [http://www.proquest.com/en-US/ ProQuest] were all used with the search terms "Addison's disease" and "physical therapy" or "exercise" and there was only one pertinent journal article. &nbsp;Jakobi et al<ref name="Jakobi">Jakobi J, Killinger D, Wolfe B, Mahon J, Rice C. Quadriceps muscle function and fatigue in women with Addison's disease. Muscle &amp;amp;amp;amp;amp;amp;amp; Nerve. August 2001;24(8):1040-1049.</ref> found that women with Addison's disease had similar maximum voluntary force of the quadriceps muscle compared to the control group of health individuals, however they had "altered contractile properties and decreased endurance compared with controls." Obviously, more research needs to be performed to determine the proper interventions that physical therapists should utilize to treat patient's with Addison's disease and also determine any limitations to treating these patients.  


<br>  
<br>  
Line 182: Line 193:
•<span style="white-space: pre" class="Apple-tab-span"> </span>Ginger works as an anti-nausea medication and helps to decrease physicial and emotional stress  
•<span style="white-space: pre" class="Apple-tab-span"> </span>Ginger works as an anti-nausea medication and helps to decrease physicial and emotional stress  


•<span style="white-space: pre" class="Apple-tab-span"> </span>Liquorice improves the activity of mineralocorticoids<br>
•<span style="white-space: pre" class="Apple-tab-span"> </span>Liquorice improves the activity of mineralocorticoids<br>  


== Differential Diagnosis  ==
== Differential Diagnosis  ==
Line 192: Line 203:
Addison’s disease presenting with idiopathic intracranial hypertension in 24-year-old woman: a case report<ref name="Sharma">Sharma D, Mukherjee1 R, Moore P, Cuthbertson DJ. Addison’s disease presenting with idiopathic intracranial hypertension in 24-year-old woman: a case report. Journal of Medical Case Reports. 2010; 4(60).</ref>&nbsp;[[http://www.touchneurology.com/files/article_pdfs/sharma_0.pdf view article at Journal of Medical Case Reports]]<br>  
Addison’s disease presenting with idiopathic intracranial hypertension in 24-year-old woman: a case report<ref name="Sharma">Sharma D, Mukherjee1 R, Moore P, Cuthbertson DJ. Addison’s disease presenting with idiopathic intracranial hypertension in 24-year-old woman: a case report. Journal of Medical Case Reports. 2010; 4(60).</ref>&nbsp;[[http://www.touchneurology.com/files/article_pdfs/sharma_0.pdf view article at Journal of Medical Case Reports]]<br>  


Premature Mortality in Patients with Addison’s Disease: A Population-Based Study&nbsp;<ref name="Bergthorsdottir">Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature Mortality in Patients with Addison’s Disease: A Population-Based Study. The Journal of Clinical Endocrinology &amp;amp;amp; Metabolism. 2006; 91(12): 4849-4853.</ref>&nbsp;[[http://jcem.endojournals.org/cgi/reprint/91/12/4849 view article at&nbsp;The Journal of Clinical Endocrinology &amp; Metabolism]]  
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study&nbsp;<ref name="Bergthorsdottir">Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature Mortality in Patients with Addison’s Disease: A Population-Based Study. The Journal of Clinical Endocrinology &amp;amp;amp;amp; Metabolism. 2006; 91(12): 4849-4853.</ref>&nbsp;[[http://jcem.endojournals.org/cgi/reprint/91/12/4849 view article at&nbsp;The Journal of Clinical Endocrinology &amp; Metabolism]]  


A three-year-old boy with X-linked adrenoleukodystrophy and congenital pulmonary adenomatoid malformation: a case report<ref name="Abdulhamid">Abdulhamid I, Saadeh S, Cakan N. A three-year-old boy with X-linked adrenoleukodystrophy and congenital pulmonary adenomatoid malformation: a case report. Journal of Medical Case Reports. 2009; 3: 9329.</ref>&nbsp;[[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809071/ view article at Journal of Medical Case Reports]]
A three-year-old boy with X-linked adrenoleukodystrophy and congenital pulmonary adenomatoid malformation: a case report<ref name="Abdulhamid">Abdulhamid I, Saadeh S, Cakan N. A three-year-old boy with X-linked adrenoleukodystrophy and congenital pulmonary adenomatoid malformation: a case report. Journal of Medical Case Reports. 2009; 3: 9329.</ref>&nbsp;[[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809071/ view article at Journal of Medical Case Reports]]  


== Resources <br>  ==
== Resources <br>  ==


National Adrenal Diseases Foundation:&nbsp;[http://www.nadf.us/ www.nadf.us]
National Adrenal Diseases Foundation:&nbsp;[http://www.nadf.us/ www.nadf.us]  


Mayo Clinic:&nbsp;[http://www.mayoclinic.com/ www.mayoclinic.com]<br>  
Mayo Clinic:&nbsp;[http://www.mayoclinic.com/ www.mayoclinic.com]<br>  


The Canadian Addison Society:&nbsp;[http://www.addisonsociety.ca/index.html www.addisonsociety.ca]
The Canadian Addison Society:&nbsp;[http://www.addisonsociety.ca/index.html www.addisonsociety.ca]  


National Endocrine and Metabolic Diseases Information Service:&nbsp;[http://endocrine.niddk.nih.gov/index.htm www.endocrine.niddk.nih.gov]
National Endocrine and Metabolic Diseases Information Service:&nbsp;[http://endocrine.niddk.nih.gov/index.htm www.endocrine.niddk.nih.gov]  


== Recent Related Research (from [http://www.ncbi.nlm.nih.gov/pubmed/ Pubmed])  ==
== Recent Related Research (from [http://www.ncbi.nlm.nih.gov/pubmed/ Pubmed])  ==


&lt;div class="researchbox"&gt;&lt;rss&gt;http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=12kswG5SFWVBwde5m7P41jWIM34qOEGxEb5FCX2J9zhajC3sAA|charset=UTF-8|short|max=10&lt;/rss&gt;&lt;/div&gt;<br>
&lt;div class="researchbox"&gt;&lt;rss&gt;http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=12kswG5SFWVBwde5m7P41jWIM34qOEGxEb5FCX2J9zhajC3sAA|charset=UTF-8|short|max=10&lt;/rss&gt;&lt;/div&gt;<br>  
<div class="researchbox"></div>
<div class="researchbox"></div>  
 
== References<br> ==
== References<br> ==


<references />
<references />  


[[Category:Bellarmine_Student_Project]]
[[Category:Bellarmine_Student_Project]]

Revision as of 04:08, 12 April 2010

Welcome to PT 635 Pathophysiology of Complex Patient Problems This is a wiki created by and for the students in the School of Physical Therapy at Bellarmine University in Louisville KY. Please do not edit unless you are involved in this project, but please come back in the near future to check out new information!!

Original Editors Elizabeth Bohnert from Bellarmine University's Pathophysiology of Complex Patient Problems project.

Lead Editors - Your name will be added here if you are a lead editor on this page.  Read more.

Definition/Description[edit | edit source]

Addison’s disease is another name for primary chronic adrenal insufficiency.  It is a condition where the adrenal cortex (the outer layer of the adrenal gland that produces mineralocorticoids, glucocorticoids, and androgens) is progressively destroyed, resulting in decreased secretions of the hormones.[1][2]  Cortisol, a glucocorticoid, and aldosterone, a mineralcorticoid, are the primary hormones that are decreased with this disease, causing body wide metabolic disorders and fluid imbalances.[1]


[Image courtesy of Britannica.com. Available at http://www.britannica.com/EBchecked/topic/6405/adrenal-gland]

Prevalence[edit | edit source]

Addison’s disease occurs in about 4 out of 100,000 Americans each year.  Even though it is seen throughout the lifespan in both genders, it most commonly occurs in middle-aged white females.

Characteristics/Clinical Presentation[edit | edit source]

Addison’s disease will develop insidiously, with the signs of the disease not developing “until at least 90% of both glands is destroyed and the levels of circulating glucocorticoids and mineralocorticoids are significantly decreased.”[2]  Some of the clinical signs and symptoms of Addison’s disease include:

Darkened pigmentation of the skin (especially of the mouth and scars), due to increased secretion of melanin-secreting hormone (MSH) corresponding with increased secretion of ACTH, which is released to try to stimulate the work of the adrenal glands[1][2]   

File:Hyperpigmentation.jpg
Hyperpigmentation of buccal mucosa in Addison's disease

Slowly developing weakness and fatigue[2][3]

Hypotension due to increased sodium excretion from decreased aldosterone secretion[1][2][3]

Severe abdominal, low back, or leg pain[1]

Gastrointestinal disturbances such as nausea, vomiting, anorexia, weight loss, and diarrhea[2][3]

Hypoglycemia due to decreased glucocorticoids causing decreased gluconeogenesis[1][2]

Decreased stress tolerance (infections, trauma, surgery, etc.)[1][2]

Salt craving

[Image courtesy of University of South Carolina School of Medicine. Available at http://pathmicro.med.sc.edu/ghaffar/tolerance2000.htm]

Associated Co-morbidities[edit | edit source]

Addison's disease can occur alone, or it can occur along with other autoimmune disorders, leading to polyendocrine syndrome[4][5].

  • Type I Diabetes Mellitus
  • Hypoparathyroidism
  • Thyroiditis
  • Pernicious Anemia
  • Vitiligo (a loss of pigment on areas of the skin)
  • Chronic Active Hepatitis


Osteoporosis is more common among people with Addison's disease compared to healthy individuals because of the medical management with long-term steroid replacement therapy.  Steroids have several effects on bones including increasing osteoclastic activity, decreasing osteoblastic formation, and decreasing the absorption of calcium in the intestines.[6]


Bone Mineral Density T-Scores[3]

Status T-Scores
Normal -1.0 or above
Osteopenia -1.0 to -2.5
Osteoporosis -2.5 or less
Severe Osteoporosis -2.5 or less with 1 or more fragility fractures







Medications[4][edit | edit source]

Acute Therapy:

Intravenously administered hydrocortisone (100 mg), repeated every 6 hours for the first 24 hours

Intravenously administered rapid infusion of saline (2-4L) during the first 12 hours

Maintenance Therapy:

Glucocorticoid Replacement: 15-20 mg of hydrocortisone daily, divided into 3 or 4 doses to simulate normal adrenal secretions

Mineralocorticoid Replacement: 0.05-0.1 mg of fludrocortisones daily

Diagnostic Tests/Lab Tests/Lab Values[edit | edit source]

Test Results That Suggest Addison's Disease[7]

 Test Result
Blood Chemistry
Serum Na < 135 mEq/L
Serum K > 5 mEq/L
Ratio of Serum Na:K <30:1
Plasma Glucose, fasting < 50 mg/dL
Plasma HCO3 < 15-20 mEq/L
BUN > 20 mg/dL
Hematology
Hct Elevated
WBC Count Low
Lymphocytes Relative lymphocytes
Eosinophils Increased
Imaging

Evidence of calcification in adrenal areas

Renal TB

Pulmonary TB

[Chart courtesy of Merck.com.  Available at http://merck.com/mmpe/sec12/ch153/ch153b.html]

Causes[edit | edit source]

There are a number of causes for Addison’s disease, however “90% of all cases are attributable to one of four diseases: autoimmune adrenalitis, tuberculosis, the acquired immune deficiency syndrome (AIDS), or metastatic cancers.”[2]  The primary sites of the metastases to the adrenal glands usually arise from carcinomas of the lungs or breasts.[2]

Systemic Involvement[edit | edit source]

add text here

Medical Management (current best evidence)[edit | edit source]

Refer to Medications

Physical Therapy Management (current best evidence)[edit | edit source]

Unfortunately, there is very little information and research pertaining to the physical therapy management of patients with Addison's disease.  The APTA's Hooked on Evidence yielded not a single article with the term "Addison's disease." Then EBSCOhost, GoogleScholar, and ProQuest were all used with the search terms "Addison's disease" and "physical therapy" or "exercise" and there was only one pertinent journal article.  Jakobi et al[8] found that women with Addison's disease had similar maximum voluntary force of the quadriceps muscle compared to the control group of health individuals, however they had "altered contractile properties and decreased endurance compared with controls." Obviously, more research needs to be performed to determine the proper interventions that physical therapists should utilize to treat patient's with Addison's disease and also determine any limitations to treating these patients.


Luckily, Goodman and Fuller[1] offer some key points for the physical therapy management of patients with Addison's disease:

  • Since these patients have a decreased response to stress, physical stress should be minimized as much as possible during activity and the treatment program should be "very gradually progressed" as the individual feels comfortable
  • Aquatics therapy should NOT be utilized with these patients because the heat and humidity of the pool will place increased demands of cortisol on their bodies to increase their blood pressure
  • Vital signs should be constantly monitored, especially when initiating or progressing an exercise program
  • Monitor for the signs of an impending addisonian crisis, which includes "dizziness, nausea, profuse sweating, elevated heart rate, and tremors or shaking"
  • Patients should be referred back to the physician if there is a suspected infection, since an infection places extra stress on the patient

Alternative/Holistic Management[9] (current best evidence)[edit | edit source]

A combination of Barago officinalis (Borage), Eleutherococcus senticosis (Siberian Ginseng), and Astragalus membranaceous (Huang Qi) help support the function of the adrenal glands and assist the body in dealing with normal stressors

Ginger works as an anti-nausea medication and helps to decrease physicial and emotional stress

Liquorice improves the activity of mineralocorticoids

Differential Diagnosis[edit | edit source]

add text here

Case Reports[edit | edit source]

Addison’s disease presenting with idiopathic intracranial hypertension in 24-year-old woman: a case report[10] [view article at Journal of Medical Case Reports]

Premature Mortality in Patients with Addison’s Disease: A Population-Based Study [11] [view article at The Journal of Clinical Endocrinology & Metabolism]

A three-year-old boy with X-linked adrenoleukodystrophy and congenital pulmonary adenomatoid malformation: a case report[12] [view article at Journal of Medical Case Reports]

Resources
[edit | edit source]

National Adrenal Diseases Foundation: www.nadf.us

Mayo Clinic: www.mayoclinic.com

The Canadian Addison Society: www.addisonsociety.ca

National Endocrine and Metabolic Diseases Information Service: www.endocrine.niddk.nih.gov

Recent Related Research (from Pubmed)[edit | edit source]

<div class="researchbox"><rss>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=12kswG5SFWVBwde5m7P41jWIM34qOEGxEb5FCX2J9zhajC3sAA%7Ccharset=UTF-8%7Cshort%7Cmax=10</rss></div>

References
[edit | edit source]

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. St. Louis: Elsevier; 2009.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 Kumar V, Abbas AK, Fausto N. Pathologic Basis of Disease. Philadelphia: Elsevier; 2005.
  3. 3.0 3.1 3.2 3.3 Goodman CC, Snyder TE. Differential Diagnosis for Physical Therapists: Screening for Referral. St. Louis: Elsevier; 2007.
  4. 4.0 4.1 Winqvist O, Rorsman F, Kampe O. Autoimmune Adrenal Insufficiency: Recognition and Management. BioDrugs. 2000; 13(2): 107-114.
  5. Loechner K. Adrenal Insufficiency and Addison's Disease. National Endocrine and Metabolic Diseases Information Service. Available at: http://endocrine.niddk.nih.gov/pubs/addison/addison.htm
  6. Adachi JD, Bensen WG, Cividino A. Corticosteroid-Induced Osteoporosis. JAMWA. 1998; 53: 1-7.
  7. Grossman A. Addison's Disease. The Merck Manuals Online Medical Library. Available at: http://merck.com/mmpe/sec12/ch153/ch153b.html
  8. Jakobi J, Killinger D, Wolfe B, Mahon J, Rice C. Quadriceps muscle function and fatigue in women with Addison's disease. Muscle &amp;amp;amp;amp;amp;amp; Nerve. August 2001;24(8):1040-1049.
  9. Addison's Disease. Native Remedies. Available at: http://www.nativeremedies.com/ailment/what-is-addisons-disease.html
  10. Sharma D, Mukherjee1 R, Moore P, Cuthbertson DJ. Addison’s disease presenting with idiopathic intracranial hypertension in 24-year-old woman: a case report. Journal of Medical Case Reports. 2010; 4(60).
  11. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature Mortality in Patients with Addison’s Disease: A Population-Based Study. The Journal of Clinical Endocrinology &amp;amp;amp; Metabolism. 2006; 91(12): 4849-4853.
  12. Abdulhamid I, Saadeh S, Cakan N. A three-year-old boy with X-linked adrenoleukodystrophy and congenital pulmonary adenomatoid malformation: a case report. Journal of Medical Case Reports. 2009; 3: 9329.